Clinical Trial Update: Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of Abnoba Viscum F 20mg in patients with malignant pleural effusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion

Drugs mentioned

• Abnoba Viscum F 20mg

Snippet

Sponsor: Abnoba Korea | Conditions: Malignant Pleural Effusion | Phase 3 | Status: COMPLETED